Amgen Inc. v. Amneal Pharmaceuticals LLC, No. 18-2414 (Fed. Cir. Jan. 7, 2020)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Amgen appeals from the district court’s judgment that Amneal Pharmaceuticals LLC and Amneal Pharmaceuti- cals of New York LLC (collectively, “Amneal”) does not in- fringe claims 1 , 2 –4, 6, 8– 12, and 14 –18 of U.S. Patent 9,375,405 (“the ’405 patent”), Piramal Healthcare UK Ltd. (“Piramal”) does not infringe claims 1 –6 and 8–20. Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (collectively, “Zydus”) cross -appeals from the court’s judg- ment that they infringe claims 1–4, 6, 8–9, 15–17, and 19 of the ’405 patent. Amgen Inc. v.